- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04978870
Diagnosis, Incidence and Consequences of PACU-Delirium (PADE-DIC)
Diagnosis, Incidence and Consequences of Postoperative Delirium in Elderly Patients in the Post-anaesthetic Care Unit
This study aims to
- determine sensitivity and specificity of the Confusion Assessment Method for Postanesthesia Care Unit (CAM-PACU)
- examine the effect of postanesthesia care unit delirium (PACU delirium) on the emergence of later onset postoperative delirium (POD) as well as cognitive recovery until one month postoperatively
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 20251
- Hamburg University Medical Centre Eppendorf
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- planned surgery in the near future
- surgery time at least 60min
Exclusion Criteria:
- intracranial surgery
- expected postoperative transfer to ICU and stay exceeding 24h
- length of postoperative stay in hospital below 24h
- insufficient German language skills
- current alcohol or drug misuse
- manifest mental illness
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1 - Validation
Group 1 will be screened for delirium during the PACU stay using the CAM-PACU.
Delirium criteria as defined by ICD-10 will be assessed in comparison.
A subgroup of patients will receive an additional delirium screening using the CAM-PACU.
This screening will be performed by another operator blinded for the results from the initial delirium screening.
|
|
2 - Cognition
Group 2 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. This group will undergo additional assessment of preoperative and postoperative cognitive function as well as a POD screening using the 3D-CAM starting at postoperative day 1 until discharge from hospital but no longer than postoperative day 5. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Group 1: Sensitivity and specificity of "Confusion Assessment Method - Postanesthetic Care Unit" (CAM-PACU)
Time Frame: 15-240 minutes postoperatively
|
in reference to International Classification of Diseases-Version 10 (ICD-10)
|
15-240 minutes postoperatively
|
|
Group 2: postoperative delirium after discharge from Postanesthetic Care Unit
Time Frame: 0-5 days postoperatively
|
3D CAM and/or medical record
|
0-5 days postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
re-test reliability
Time Frame: 15-240 minutes postoperatively
|
CAM-PACU
|
15-240 minutes postoperatively
|
|
cognitive performance
Time Frame: before, 7 and 30 days postoperatively
|
Montreal Cognitive Assessment (MoCA, 0-30 points, higher score = better outcome), Cognitive Telephone Screening Instrument (COGTEL), Patient Reported Outcomes Measurement Information System (PROMIS Neuro QoL)
|
before, 7 and 30 days postoperatively
|
|
postoperative complications
Time Frame: 30 days postoperatively
|
European Perioperative Clinical Outcome (EPCO) definitions; Standardised Endpoints in Perioperative Medicine - Core Outcome Measures in Perioperative and Anaesthetic Care (Step-COMPAC) definitions
|
30 days postoperatively
|
|
feasibility of delirium screening by questioning of medical staff
Time Frame: before, 3 and 12 months after implementation of CAM-PACU
|
self-designed questionnaire
|
before, 3 and 12 months after implementation of CAM-PACU
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-10331-BO-ff
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.